2-Bromo-1-(3-methoxyphenyl)ethanone structure
|
Common Name | 2-Bromo-1-(3-methoxyphenyl)ethanone | ||
|---|---|---|---|---|
| CAS Number | 5000-65-7 | Molecular Weight | 229.071 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 278.1±15.0 °C at 760 mmHg | |
| Molecular Formula | C9H9BrO2 | Melting Point | 60-62 °C(lit.) | |
| MSDS | Chinese USA | Flash Point | 122.0±20.4 °C | |
| Symbol |
GHS05, GHS07 |
Signal Word | Danger | |
| Name | 3'-methoxyphenacyl bromide |
|---|---|
| Synonym | More Synonyms |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 278.1±15.0 °C at 760 mmHg |
| Melting Point | 60-62 °C(lit.) |
| Molecular Formula | C9H9BrO2 |
| Molecular Weight | 229.071 |
| Flash Point | 122.0±20.4 °C |
| Exact Mass | 227.978592 |
| PSA | 26.30000 |
| LogP | 2.37 |
| Vapour Pressure | 0.0±0.6 mmHg at 25°C |
| Index of Refraction | 1.554 |
| InChIKey | IOOHBIFQNQQUFI-UHFFFAOYSA-N |
| SMILES | COc1cccc(C(=O)CBr)c1 |
| Storage condition | 0-6°C |
| Symbol |
GHS05, GHS07 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H314-H335 |
| Precautionary Statements | P261-P280-P305 + P351 + P338-P310 |
| Personal Protective Equipment | Eyeshields;Faceshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges |
| Hazard Codes | C:Corrosive; |
| Risk Phrases | R22;R34 |
| Safety Phrases | S26-S27-S28-S36/37/39-S45 |
| RIDADR | UN 3261 8/PG 2 |
| WGK Germany | 3 |
| Packaging Group | III |
| Hazard Class | 8 |
| HS Code | 2914700090 |
| Precursor 1 | |
|---|---|
| DownStream 10 | |
| HS Code | 2914700090 |
|---|---|
| Summary | HS: 2914700090 halogenated, sulphonated, nitrated or nitrosated derivatives of ketones and quinones, whether or not with other oxygen function Tax rebate rate:9.0% Supervision conditions:none VAT:17.0% MFN tariff:5.5% General tariff:30.0% |
|
The influence of genetic polymorphism of Cyp2c19 isoenzyme on the pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases.
J. Clin. Pharmacol. 54(8) , 874-80, (2014) An extensive investigation on pharmacokinetics of clopidogrel and its metabolites as well as pharmacodynamics of the drug was performed in patients with cardiovascular disease carrying various alleles... |
|
|
Identification of alcohol-dependent clopidogrel metabolites using conventional liquid chromatography/triple quadrupole mass spectrometry.
Rapid Commun. Mass Spectrom. 28(11) , 1285-92, (2014) Clopidogrel (CLO) is a prodrug used to prevent ischemic events in patients undergoing percutaneous coronary intervention or with myocardial infarction. A previous study found ethyl clopidogrel (ECLO) ... |
|
|
CYP-independent inhibition of platelet aggregation in rabbits by a mixed disulfide conjugate of clopidogrel.
Thromb. Haemost. 112(6) , 1304-11, (2014) Dual antiplatelet therapy with clopidogrel and aspirin has been the standard of care in the United States for patients with acute coronary syndromes (ACS) and/or undergoing percutaneous coronary inter... |
| 2-Bromo-1-(3-methoxyphenyl)ethanone |
| Ethanone, 2-bromo-1-(3-methoxyphenyl)- |
| 3'-Methoxyphenacyl BroMide |
| EINECS 225-666-1 |
| 2-Bromo-3‘-methoxyacetophenone |
| 3-(Bromoacetyl)Anisole |
| 2-Bromo-3′-methoxyacetophenone |
| MFCD00000199 |